Danna nan don nuna banners ɗin ku akan wannan shafin kuma ku biya kawai don nasara

Labaran Waya

Gagarumin Ingantawa a cikin Tsananin Cuta don Atopic Dermatitis

Written by edita

A cikin makonni 16, kashi 70 cikin 75 na marasa lafiya masu matsakaici-zuwa mai tsanani atopic dermatitis (AD) suna karɓar lebrikizumab hade tare da daidaitattun corticosteroids na kulawa (TCS) sun sami ci gaba aƙalla kashi 75 cikin 4 na ci gaba a cikin tsananin cutar (EASI-13*) gwajin ADhere, Eli Lilly da Kamfanin (NYSE: LLY) sun sanar a yau a taron XNUMXth Annual Revolutionizing Atopic Dermatitis (RAD). Lebrikizumab, mai binciken IL-XNUMX mai bincike, ya kuma nuna haɓakawa a cikin ƙaiƙayi, tsangwama na barci, da kuma ingancin rayuwa lokacin da aka hade tare da TCS, idan aka kwatanta da placebo da TCS.

"Bayanan ADhere na yau, tare da sakamako daga nazarin nazarin monotherapy ADvocate, sun nuna yiwuwar lebrikizumab don rage nauyin cututtuka da kuma ba da taimako ga mutanen da ke fama da cututtukan cututtukan cututtukan da ba a kula da su ba lokacin da aka yi amfani da su kadai ko a hade tare da magunguna," in ji Eric Simpson, MD, MCR. Farfesa na Dermatology da Daraktan Bincike na Clinical a Oregon Health & Science University a Portland, kuma babban mai bincike na ADhere. "Lebrikizumab musamman yana hari kan hanyar IL-13, wanda ke taka muhimmiyar rawa a cikin wannan cuta mai saurin kumburi. Waɗannan sakamakon sun ƙarfafa fahimtar mu game da lebrikizumab a cikin ƙwayar cuta ta atopic kuma suna taimakawa wajen kafa shi a matsayin sabon zaɓin magani mai yiwuwa.

Lebrikizumab wani labari ne, maganin rigakafi na monoclonal (mAb) wanda ke ɗaure da furotin na interleukin 13 (IL-13) tare da babban alaƙa don hana samuwar IL-13Rα1 / IL-4Rα (Nau'in 2 receptor) wanda ke toshe siginar ƙasa ta IL. -13 pathway.1-5 IL-13 yana taka muhimmiyar rawa a cikin nau'in kumburi na nau'in 2 a AD.6,7 A AD, IL-13 yana ƙarƙashin alamun da alamun bayyanar cututtuka ciki har da rashin aiki na shinge na fata, ƙaiƙayi, kamuwa da cuta da wuya, wuraren daɗaɗɗen fata. .8

Daga cikin marasa lafiya da ke shan lebrikizumab da TCS, kashi 41 sun sami bayyananniyar fata ko kusan bayyanan fata (IGA) a cikin makonni 16 idan aka kwatanta da kashi 22 na marasa lafiya da ke shan placebo da TCS. A makonni 16, kashi 70 na marasa lafiya da ke shan lebrikizumab tare da TCS sun sami amsa EASI-75 idan aka kwatanta da kashi 42 na shan placebo da TCS. Bambance-bambance tsakanin marasa lafiya da ke karɓar lebrikizumab a hade tare da TCS da placebo tare da TCS an lura da su a farkon makonni hudu don EASI-75.

Marasa lafiya da aka yi amfani da su tare da lebrikizumab tare da TCS kuma sun sami ci gaba mai mahimmanci na ƙididdiga a cikin mahimman abubuwan ƙarshe na biyu ciki har da cire fata da ƙaiƙayi, tsangwama na ƙaiƙayi akan barci, da ingancin matakan rayuwa, idan aka kwatanta da placebo tare da TCS. An lura da bambance-bambance masu ma'ana na asibiti a farkon makonni huɗu don ƙaiƙayi, tsangwama na ƙaiƙayi akan barci, da ingancin matakan rayuwa.

Sakamakon aminci ya yi daidai da binciken lebrikizumab a baya a AD. Marasa lafiya da ke shan lebrikizumab tare da TCS, idan aka kwatanta da placebo da TCS, sun ba da rahoton mafi girman adadin abubuwan da ba su da kyau (lebrikizumab da TCS: 43%, placebo da TCS: 35%). Yawancin al'amuran da ba su da kyau sun kasance masu sauƙi ko matsakaici a cikin tsanani kuma marasa mahimmanci kuma ba su haifar da dakatar da magani ba. Mafi yawan al'amuran da suka fi faruwa ga waɗanda ke kan lebrikizumab sune conjunctivitis (5%) da ciwon kai (5%).

"Lilly yana aiki don ƙarfafa mutanen da ke da cututtukan fata, irin su atopic dermatitis, don yin rayuwarsu zuwa ga mafi kyau," in ji Lotus Mallbris, MD, Ph.D., mataimakin shugaban ci gaban rigakafi na duniya da kuma harkokin kiwon lafiya a Lilly. . "Mun fahimci mahimmancin buƙatar ƙarin zaɓuɓɓuka ga mutanen da ba za a iya shawo kan cutar su tare da abubuwan da ke faruwa ba. Muna sa ran ganin cikakken sakamako daga babban shirinmu na mataki na 3 da kuma ci gaban lebrikizumab a duk duniya."

Kwanan nan Lilly ta sanar da bayanan makonni 16 daga nazarin ADvocate mai gudana, kuma an gabatar da ingantaccen gabatar da sakamako a RAD 2022. Bugu da ƙari, za a bayyana bayanan dogon lokaci daga nazarin ADvocate a cikin watanni masu zuwa.

“Wadannan sakamakon wani mataki ne na gaba a cikin yunƙurinmu na isar da sabbin hanyoyin kwantar da hankali waɗanda ke kawo canji mai ma'ana ga marasa lafiya. Muna sa ran sanar da sabbin matakai masu ban sha'awa a cikin watanni masu zuwa," in ji Karl Ziegelbauer, Ph.D., Babban Jami'in Kimiyya na Almirall SA.

Lilly tana da keɓantaccen haƙƙi don haɓakawa da kasuwancin lebrikizumab a cikin Amurka da sauran ƙasashen duniya a wajen Turai. Almirall ya ba da lasisin haƙƙin haɓakawa da tallata lebrikizumab don maganin alamun cututtukan fata, gami da AD, a Turai.

Shafin Farko

Game da marubucin

edita

Edita a shugaba na eTurboNew ita ce Linda Hohnholz. Ta dogara ne a HQ eTN a Honolulu, Hawaii.

Leave a Comment

Share zuwa...